The United States Patent and Trademark Office (USPTO) announced on Oct. 4, 2022, that it is extending the Motion to Amend (MTA) Pilot Program through September 16, 2024. The MTA Pilot Program was initiated on March 15, 2019. It was previously extended on September 16, 2021. The MTA Pilot Program provides two options for a patent owner who files an MTA in an America Invents Act (AIA) trial proceeding before the Patent Trial and Appeal Board (PTAB). The program provides a patent owner who files an MTA with options to (1) request preliminary guidance from the PTAB on the MTA and (2) to file a revised MTA. The MTA Pilot Program also provides timelines for briefing to accommodate these options.
The USPTO plans to issue a Request for Comments to gather feedback and suggestions on the program and on amendment practice generally. The USPTO also wants comments in order to determine whether to make the program permanent. The requirements for the program remain unchanged.
Motion to Amend studies and data are available on the USPTO website: https://www.uspto.gov/patents/ptab/motions-amend-study
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
